ETF Home ETF List Shorted Stocks Home About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for NBIX

Stock NameNeurocrine Biosciences Inc
TickerNBIX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS64125C1099
LEI549300FECER0XBN49756

Show aggregate NBIX holdings

News associated with NBIX

Sum Up The Parts: SCHG Could Be Worth $34
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:23:31
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Maryland State Retirement & Pension System
Maryland State Retirement & Pension System lowered its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 12.5% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,661 shares of the company’s stock after selling 663 shares during the quarter. Maryland […] - 2025-08-15 05:24:56
Charles Schwab Investment Management Inc. Purchases 13,216 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Charles Schwab Investment Management Inc. raised its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 775,773 shares of the company’s stock after acquiring an additional 13,216 shares during the quarter. Charles […] - 2025-08-13 05:10:46
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Blair William & Co. IL
Blair William & Co. IL cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.7% in the first quarter, Holdings Channel reports. The fund owned 6,214 shares of the company’s stock after selling 242 shares during the period. Blair William & Co. IL’s holdings in Neurocrine Biosciences were worth $687,000 at the […] - 2025-08-11 05:52:52
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Federated Hermes Inc.
Federated Hermes Inc. trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 72.9% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 9,441 shares of the company’s stock after selling 25,402 shares during the quarter. Federated Hermes Inc.’s […] - 2025-08-07 05:22:58
Natixis Advisors LLC Sells 292 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Natixis Advisors LLC lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.9% in the first quarter, Holdings Channel.com reports. The institutional investor owned 33,312 shares of the company’s stock after selling 292 shares during the period. Natixis Advisors LLC’s holdings in Neurocrine Biosciences were worth $3,684,000 at the end of the […] - 2025-08-07 04:49:07
Neurocrine (NBIX) Q2 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo - 2025-08-05 01:16:10
Neurocrine (NBIX) Q2 Revenue Jumps 17%
Key PointsNon-GAAP earnings per share of $1.65 for Q2 2025 vastly exceeded the analyst estimate of $0.96. - 2025-08-01 01:15:16
13,202 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Bought by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund acquired 13,202 shares of the company’s stock, valued at approximately $1,460,000. Other hedge funds and other institutional investors have also recently bought and sold shares of the company. […] - 2025-07-24 06:50:57
HighPoint Advisor Group LLC Purchases 366 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
HighPoint Advisor Group LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 15.0% during the first quarter, Holdings Channel.com reports. The fund owned 2,812 shares of the company’s stock after acquiring an additional 366 shares during the quarter. HighPoint Advisor Group LLC’s holdings in Neurocrine Biosciences were worth $302,000 […] - 2025-07-24 05:51:14
Neurocrine Biosciences (NASDAQ:NBIX) Now Covered by Analysts at Truist Financial
Truist Financial initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report report published on Monday, Marketbeat reports. The firm issued a buy rating and a $163.00 price target on the stock. NBIX has been the subject of several other reports. Royal Bank Of Canada reaffirmed an “outperform” rating and […] - 2025-07-22 04:28:48
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Trimmed by Cerity Partners LLC
Cerity Partners LLC decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 33,361 shares of the company’s stock after selling 8,376 shares during the quarter. Cerity Partners LLC’s holdings in […] - 2025-07-18 04:55:08
Ingrid Delaet Sells 457 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the transaction, the insider directly owned 4,730 shares in the […] - 2025-07-14 07:16:47
Bank of New York Mellon Corp Has $91.65 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Bank of New York Mellon Corp lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 4.8% during the first quarter, HoldingsChannel reports. The fund owned 828,682 shares of the company’s stock after selling 41,608 shares during the quarter. Bank of New York Mellon Corp’s holdings in Neurocrine Biosciences were worth $91,652,000 as […] - 2025-07-11 05:40:57
Principal Financial Group Inc. Has $27.48 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Principal Financial Group Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 248,420 shares of the company’s stock after selling 4,049 shares during the period. Principal Financial Group Inc. owned 0.25% of Neurocrine Biosciences […] - 2025-07-09 05:51:40
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of “Moderate Buy” by Analysts
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and nineteen have given a buy recommendation to the company. The average 12 […] - 2025-07-09 03:09:50
First Horizon Advisors Inc. Has $43,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 55.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 385 shares of the company’s stock after selling 480 shares during the quarter. First Horizon Advisors […] - 2025-07-08 05:49:06
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 20,362 Shares
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 20,362 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total value of $2,649,707.06. Following the completion of the sale, the insider owned 18,289 shares of the company’s […] - 2025-07-08 05:06:50
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by KBC Group NV
KBC Group NV lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.5% in the 1st quarter, Holdings Channel reports. The fund owned 13,835 shares of the company’s stock after selling 495 shares during the period. KBC Group NV’s holdings in Neurocrine Biosciences were worth $1,530,000 as of its most recent filing […] - 2025-07-04 06:58:45
New York State Teachers Retirement System Lowers Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
New York State Teachers Retirement System lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.9% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 108,481 shares of the company’s stock after selling 2,055 shares during the quarter. New York State Teachers Retirement System’s holdings in Neurocrine Biosciences were worth $11,998,000 […] - 2025-07-04 06:14:58
Amalgamated Bank Has $5.28 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Amalgamated Bank lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 3.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,719 shares of the company’s stock after selling 1,895 shares during the quarter. Amalgamated Bank’s holdings in Neurocrine Biosciences were […] - 2025-07-03 06:14:49
Sumitomo Mitsui Trust Group Inc. Sells 1,399 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Sumitomo Mitsui Trust Group Inc. reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 0.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 231,458 shares of the company’s stock after selling 1,399 shares during the quarter. Sumitomo Mitsui Trust […] - 2025-07-03 05:35:01
Golden State Wealth Management LLC Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Golden State Wealth Management LLC increased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 116.9% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397 shares of the company’s stock after purchasing an additional 214 shares during the quarter. […] - 2025-07-02 05:01:01
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc. raised its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 19,388 shares of the company’s stock after buying an additional 447 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Neurocrine Biosciences were worth $2,144,000 as […] - 2025-06-27 05:10:49
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Retirement Systems of Alabama
Retirement Systems of Alabama cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.4% in the 1st quarter, Holdings Channel reports. The firm owned 121,352 shares of the company’s stock after selling 1,755 shares during the period. Retirement Systems of Alabama’s holdings in Neurocrine Biosciences were worth $13,422,000 at the […] - 2025-06-23 05:04:51
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by QRG Capital Management Inc.
QRG Capital Management Inc. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 20,062 shares of the company’s stock after buying an additional 1,330 shares […] - 2025-06-20 06:54:59
Sowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company’s stock, valued at approximately $529,000. Other institutional investors and hedge funds […] - 2025-06-20 05:29:06
Trust Point Inc. Sells 660 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Trust Point Inc. decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 26.6% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,823 shares of the company’s stock after selling 660 shares during the period. Trust Point Inc.’s holdings in […] - 2025-06-19 05:35:02
XBI, EXAS, NBIX, NTRA: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $443.9 million dollar outflow -- that's a 8.8% decrease week over week - 2025-06-17 11:54:37
Merit Financial Group LLC Acquires 345 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
Merit Financial Group LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 9.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,153 shares of the company’s stock after purchasing an additional 345 shares during the quarter. Merit Financial Group […] - 2025-06-11 05:00:51

iShares Healthcare Innovation UCITS ETF USD (Acc) NBIX holdings

DateNumber of NBIX Shares HeldBase Market Value of NBIX SharesLocal Market Value of NBIX SharesChange in NBIX Shares HeldChange in NBIX Base ValueCurrent Price per NBIX Share HeldPrevious Price per NBIX Share Held
2026-02-09 (Monday)121,844USD 17,004,549USD 17,004,549
2026-02-06 (Friday)121,326NBIX holding increased by 519USD 17,131,231NBIX holding increased by 504564USD 17,131,231519USD 504,564 USD 141.2 USD 137.63
2026-02-02 (Monday)120,807USD 16,626,667NBIX holding increased by 189667USD 16,626,6670USD 189,667 USD 137.63 USD 136.06
2026-01-30 (Friday)120,807NBIX holding decreased by -1038USD 16,437,000NBIX holding decreased by -372736USD 16,437,000-1,038USD -372,736 USD 136.06 USD 137.96
2026-01-29 (Thursday)121,845USD 16,809,736NBIX holding increased by 495909USD 16,809,7360USD 495,909 USD 137.96 USD 133.89
2026-01-27 (Tuesday)121,845USD 16,313,827NBIX holding decreased by -75544USD 16,313,8270USD -75,544 USD 133.89 USD 134.51
2026-01-26 (Monday)121,845USD 16,389,371NBIX holding decreased by -203481USD 16,389,3710USD -203,481 USD 134.51 USD 136.18
2026-01-23 (Friday)121,845NBIX holding increased by 519USD 16,592,852NBIX holding decreased by -73701USD 16,592,852519USD -73,701 USD 136.18 USD 137.37
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of NBIX by Blackrock for IE00BYZK4776

Show aggregate share trades of NBIX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2026-02-06BUY519 141.200* 129.20
2026-01-30SELL-1,038137.530134.960 135.217USD -140,355 129.14 Loss of -6,305 on sale
2026-01-23BUY519138.735135.410 135.743USD 70,450 129.04
2026-01-20BUY519134.770129.171 129.731USD 67,330 128.96
2026-01-07BUY1,036142.155137.600 138.056USD 143,026 128.75
2026-01-02BUY1,013142.070138.640 138.983USD 140,790 128.63
2025-12-30BUY516143.180140.560 140.822USD 72,664 128.52
2025-12-19SELL-2,570145.940141.000 141.494USD -363,640 128.06 Loss of -34,536 on sale
2025-12-17SELL-514150.470141.610 142.496USD -73,243 127.93 Loss of -7,485 on sale
2025-12-16SELL-514155.230148.135 148.844USD -76,506 127.84 Loss of -10,796 on sale
2025-12-03BUY712154.350150.260 150.669USD 107,276 126.73
2025-12-02BUY511153.790150.855 151.148USD 77,237 126.61
2025-12-01BUY1,022153.290149.580 149.951USD 153,250 126.49
2025-11-28BUY592153.700150.410 150.739USD 89,237 126.37
2025-11-14SELL-1,024146.375142.990 143.329USD -146,768 125.52 Loss of -18,233 on sale
2025-10-24SELL-1,018144.000144.420 144.378USD -146,977 123.85 Loss of -20,898 on sale
2025-09-11BUY509143.600143.820 143.798USD 73,193 121.52
2025-07-08SELL-509128.740129.780 129.676USD -66,005 120.09 Loss of -4,878 on sale
2025-06-24SELL-507128.180128.500 128.468USD -65,133 119.60 Loss of -4,496 on sale
2025-06-23BUY60125.800127.990 127.771USD 7,666 119.55
2025-06-20BUY13,493126.550128.380 128.197USD 1,729,762 119.50
2025-06-11SELL-451124.170125.510 125.376USD -56,545 119.18 Loss of -2,793 on sale
2025-05-30SELL-451123.020123.930 123.839USD -55,851 118.82 Loss of -2,262 on sale
2025-05-21BUY451120.560122.420 122.234USD 55,128 118.67
2025-05-14SELL-2,706118.780121.850 121.543USD -328,895 118.58 Loss of -8,024 on sale
2025-04-30SELL-451107.690107.980 107.951USD -48,686 118.98 Profit of 4,976 on sale
2025-04-28SELL-451106.460108.330 108.143USD -48,772 119.23 Profit of 5,000 on sale
2025-04-25SELL-451106.730107.540 107.459USD -48,464 119.36 Profit of 5,366 on sale
2025-04-11SELL-2,71290.87091.280 91.239USD -247,440 121.07 Profit of 80,902 on sale
2025-04-08SELL-1,35387.54096.000 95.154USD -128,743 122.10 Profit of 36,459 on sale
2025-04-07BUY1,28893.25096.440 96.121USD 123,804 122.44
2025-03-31SELL-886110.600112.600 112.400USD -99,586 123.27 Profit of 9,629 on sale
2025-03-21SELL-886111.920112.530 112.469USD -99,648 123.98 Profit of 10,201 on sale
2025-03-12SELL-443109.070109.560 109.511USD -48,513 125.40 Profit of 7,037 on sale
2025-02-28SELL-443118.720118.930 118.909USD -52,677 127.02 Profit of 3,594 on sale
2025-02-25BUY443115.900120.000 119.590USD 52,978 127.54
2025-02-20SELL-443116.110117.680 117.523USD -52,063 128.03 Profit of 4,653 on sale
2025-02-19BUY886114.260114.930 114.863USD 101,769 128.28
2025-02-18BUY443113.970115.820 115.635USD 51,226 128.55
2024-12-30BUY1,434137.060138.650 138.491USD 198,596 123.05
2024-12-06SELL-434128.140128.930 128.851USD -55,921 122.48 Loss of -2,764 on sale
2024-12-04SELL-434127.740127.900 127.884USD -55,502 122.15 Loss of -2,487 on sale
2024-12-03SELL-868125.440126.980 126.826USD -110,085 122.03 Loss of -4,162 on sale
2024-11-21SELL-434125.000126.130 126.017USD -54,691 120.18 Loss of -2,535 on sale
2024-11-20SELL-433123.290124.010 123.938USD -53,665 120.00 Loss of -1,703 on sale
2024-11-19BUY267119.130119.790 119.724USD 31,966 120.06
2024-11-18SELL-1,724117.620118.320 118.250USD -203,863 120.21 Profit of 3,375 on sale
2024-11-12SELL-431127.010128.240 128.117USD -55,218 119.75 Loss of -3,604 on sale
2024-11-07SELL-431123.980126.650 126.383USD -54,471 118.97 Loss of -3,196 on sale
2024-11-05SELL-862121.530122.000 121.953USD -105,123 118.16 Loss of -3,270 on sale
2024-10-28SELL-431116.200117.950 117.775USD -50,761 116.01 Loss of -762 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of NBIX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19138,3040280,71449.3%
2025-09-18207,77644,506326,19463.7%
2025-09-17106,323343194,59754.6%
2025-09-1697,81119,146256,98038.1%
2025-09-1573,3630197,45737.2%
2025-09-1271,8171,305193,96837.0%
2025-09-1187,2040250,36934.8%
2025-09-10117,0990288,60540.6%
2025-09-09123,3791,879226,94154.4%
2025-09-08213,6691,667350,78760.9%
2025-09-05269,8828,988447,93060.3%
2025-09-04193,322481275,12970.3%
2025-09-03210,597108556,90537.8%
2025-09-02183,31915,512318,15057.6%
2025-08-29101,0617,590154,07965.6%
2025-08-28127,383487193,56165.8%
2025-08-27137,4541,818217,03363.3%
2025-08-26170,0223,558291,09658.4%
2025-08-25124,1533,639195,47663.5%
2025-08-22126,62910,885196,28864.5%
2025-08-21119,2451,265200,99059.3%
2025-08-20135,1384,637230,01058.8%
2025-08-19186,010535287,33064.7%
2025-08-18162,0387,351232,60969.7%
2025-08-15140,024100220,19963.6%
2025-08-14290,907253363,13980.1%
2025-08-13356,4048,730466,19176.5%
2025-08-12303,9754,067434,64169.9%
2025-08-11279,1915,617413,02767.6%
2025-08-08338,3850490,22069.0%
2025-08-07341,7192486,06070.3%
2025-08-06162,49452290,74155.9%
2025-08-05127,812122285,40144.8%
2025-08-04184,650798554,60133.3%
2025-08-01384,652274613,13762.7%
2025-07-31795,02721,403,51956.6%
2025-07-30277,359199566,94248.9%
2025-07-29235,4831,232479,50449.1%
2025-07-28128,7961,272304,76342.3%
2025-07-25164,9590533,68230.9%
2025-07-24143,137442360,99139.7%
2025-07-23127,087250336,56737.8%
2025-07-22110,378700199,61455.3%
2025-07-2194,76891171,48155.3%
2025-07-18136,185216238,83657.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy